Dear Colleagues, This may interest some of you. Brian ---------- Forwarded message ---------- From: Herbertz, Torsten <therbertz@formatherapeutics.com> Date: Wed, May 22, 2013 at 12:51 PM Subject: superior CADD candidates To: "shoichet@cgl.ucsf.edu" <shoichet@cgl.ucsf.edu>, " klebe@staff.uni-marburg.de" <klebe@staff.uni-marburg.de>, " klebe@mailer.uni-marburg.de" <klebe@mailer.uni-marburg.de> Dear Prof. Shoichet & Klebe,**** ** ** I am reaching out to ask for your help in identifying exceptional candidates for open CADD positions at Forma Therapeutics ( http://formatherapeutics.com/) in the Boston area & making you aware that we would consider highly recommended post-docs in your labs.**** I made your acquaintance all the way back in 2002 at the Erice Gene-to-drugs xray crystallography conference and we have encountered each other on numerous occasions like the CADD GRC. Furthermore, I have been following your published work with much interest. Your laboratories produce very important results and insights that I attempt to apply & adapt to my own work, particularly here at Forma, where I have the privilege of leading a growing CompChem group (with 5 current members).**** We are mostly interested in candidates who have demonstrated small molecule drug discovery experience, a very sound understanding of medicinal chemistry and how to work with medchemists. Furthermore, good organic chemistry & biophysical chemistry are more important than method development, chemoinformatics, ….**** Forma is an oncology-focused relatively young (~5 years) and small (~110 people) company located in Watertown, MA.**** We are interested in many molecular target classes relevant to cancer biology, including cancer metabolism, epigenetics, protein-protein interactions and protein homeostasis to name a few.**** Computational chemistry is an integral part of our discovery paradigm; we generally only work on structure-enabled targets. Every project team includes a compchemists, who is invested as much as medicinal chemists, biologist and biochemists. In general, we follow two strategies in parallel: lead identification and chemical biology - in essence finding a tool compound for target validation. The hope is to push interesting chemical matter as far as we can toward pre-clinical development.**** This is a brief & simplified introduction to Forma and I hope that it convinces you that Forma is an exciting place to do drug discovery.**** I hope that you can provide interesting candidate leads for me to follow up. **** Any assistance that you can extend is deeply appreciated.**** ** ** Best regards,**** ** ** Torsten Herbertz, PhD**** Principal Scientist**** ** ** Forma Therapeutics, Inc.**** 500 Arsenal Street, Suite 100**** Watertown, MA 02472**** Email: therbertz@formatherapeutics.com <dmillan@formatherapeutics.com>**** Office: +1-857-209-2327**** www.formatherapeutics.com**** [image: Description: cid:image001.jpg@01CA92A2.4F452810]**** ** ** -- Brian Shoichet Professor University of California, San Francisco Dept. of Pharmaceutical Chemistry phone: 415-514-4126; fax: 415-514-4260 http://shoichetlab.compbio.ucsf.edu
